Silence Therapeutics reports Q3 2026 results and signs definitive acquisition agreement with Merck KGaA
Silence Therapeutics announced positive topline Phase 2 results for its divesiran therapy on August 10, 2026. On October 19, 2026 the company entered a definitive all‑cash agreement to be acquired by Merck KGaA, with closing expected in the first quarter of 2027. The Q3 2026 financial release showed cash of $247.7 million, a net loss of $12.4 million and GAAP EPS of –$0.08.
Why it matters
The acquisition will provide shareholders with cash proceeds and integrate Silence’s siRNA platform into Merck’s pipeline, potentially enhancing Merck’s market position in RNA therapeutics (the company states the transaction is subject to customary closing conditions). The Q3 results also illustrate the company’s reduced expense base and improved cash position ahead of the deal.
Key facts
- 1Positive topline Phase 2 results for divesiran were reported on August 10, 2026. finanznachrichten.de
- 2Silence entered a definitive agreement to be acquired by Merck KGaA on October 19, 2026. finanznachrichten.de
- 3The acquisition is expected to close in the first quarter of 2027, subject to customary closing conditions. finanznachrichten.de
- 4Cash and cash equivalents were $247.7 million as of September 30, 2026. finanznachrichten.de
- 5Net loss for the quarter was $12.4 million, or $0.08 basic and diluted loss per share. finanznachrichten.de
- 6Research and development expenses were $9.3 million for the quarter. finanznachrichten.de
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.